111
Views
14
CrossRef citations to date
0
Altmetric
Original Research

Vitamin D status is associated with muscle strength and quality of life in patients with COPD: a seasonal prospective observation study

, , , , , , , & show all
Pages 2613-2622 | Published online: 28 Aug 2018

Abstract

Background

Owing to hospitalization, reduced functional capacity and consequently, less sunlight exposure, suboptimal vitamin D status (25-hydroxyvitamin D [25(OH)D]⩽50 nmol/L) is prevalent among COPD patients.

Objective

This study aimed to investigate seasonal changes in vitamin D status and any associated changes in fat-free mass (FFM), muscle strength and quality of life (QoL) in COPD patients.

Patients and methods

COPD patients living in Northern Ireland (n=51) completed study visits at the end of winter (March/April) and at the end of summer (September/October), corresponding to the nadir and peak of vitamin D status, respectively. At both time points, serum concentration of 25(OH)D was quantified by liquid chromatography-tandem mass spectrometry, FFM (kg) was measured using bioelectrical impedance and muscle strength (kg) was measured using handgrip dynamometry. QoL was assessed using the validated St George’s Respiratory Questionnaire.

Results

Mean±SD 25(OH)D concentration was significantly higher at the end of summer compared to the end of winter (52.5±30.5 nmol/L vs 33.7±28.4 nmol/L, P<0.001); and house- bound patients had significantly lower 25(OH)D concentration compared to nonhousebound patients at the end of summer (42.9±4.2 vs 57.2±9.9 nmol/L; P⩽0.001). Muscle strength (at both time points) and QoL (end of summer only) were positively predicted by 25(OH)D concentration, independent of age, sex and smoking status.

Conclusion

This study highlights the need for health policies to include a recommendation for year-round vitamin D supplementation in housebound COPD patients, and wintertime supplementation in nonhousebound patients, to maintain optimal 25(OH)D concentrations to protect musculoskeletal health. Furthermore, an optimal vitamin D status may have potential benefits for QoL in these patients.

Plain language summary

Why was the study done? To establish if there was seasonal variation in blood levels of vitamin D in COPD patients. Current patient recommendations suggest supplementation during the winter period when vitamin D is at its lowest. The researchers also wanted to establish if there were any links between vitamin D, muscle health and quality of life (QoL) in this population.

What did the researchers do and find? Data were collected from a group of COPD patients living in Northern Ireland. They found that vitamin D levels were low in the majority of patients. Vitamin D was lower in the winter vs summer and in housebound patients vs those who were not housebound. Patients with higher vitamin D levels had better muscle strength and better QoL compared to those with lower levels.

What do these results mean? These results suggest that there is a need for year-round vitamin D supplementation in COPD patients, especially those who do not regularly get outdoors. Ensuring better vitamin D levels may be beneficial for muscle strength and QoL in COPD patients. Revised policies and education are needed for this patient group to help maintain optimal vitamin D levels.

Introduction

COPD is the fourth leading cause of mortality globallyCitation1 with an estimated prevalence of 251 million cases in 2016. COPD is characterized by progressive and persistent airflow limitation accompanied by an enhanced chronic inflammatory response and is primarily caused by smoking and environmental exposure to smoke.Citation2 Increased rates of respiratory infections and inflammatory exacerbations in COPD patients result in more frequent hospital stays and more time spent indoors. As a result, decreased sunlight exposure, along with a poor dietary intake, glucocorticoid medication, aging, lower vitamin D storage from muscle or fat and renal dysfunction, places this patient group at high risk of vitamin D deficiency (25-hydroxyvitamin D [25(OH)D] concentrations ⩽25 nmol/L).Citation3Citation5 One study has reported vitamin D insufficiency (25(OH)D ⩽50 nmol/L) in 58% of COPD patients, even during summer monthsCitation6 with others reporting vitamin D insufficiency in up to 79% of moderate to severely affected COPD patients within Northern Ireland.Citation7

Vitamin D deficiency, in turn, has been associated with increased rates of exacerbations and hospitalization in COPD patients.Citation8,Citation9 Recent meta-analyses have concluded that vitamin D deficiency is directly associated with COPD disease severity and vitamin D supplementation may prevent exacerbations.Citation10Citation12 It is purported that this association is mediated through the immunomodulatory effects of vitamin DCitation13 by shifting the inflammatory balance from a pro-inflammatory T-helper cell 1 profile toward a more anti-inflammatory T-helper cell 2 profile.Citation14,Citation15 Therefore, achieving optimal vitamin D status might not only help prevent comorbidities, such as osteoporosis in COPD patients,Citation16 but may also help prevent respiratory infections and exacerbations,Citation9 which have been shown to be predictive of a higher mortality risk in this patient group.Citation17

Furthermore, COPD patients present with a severe reduction in physical performance and capacity for physical activity, mostly owing to impaired respiratory and muscle functions,Citation18,Citation19 resulting in a significant deterioration in quality of life (QoL).Citation20 Patients with moderate to severe COPD often present with muscle wastage and severe muscle weakness, which can manifest as cachexia or sarcopenia, both of which have been associated with increased mortality risk and disease severity.Citation21,Citation22 Cachexia in COPD patients is typically diagnosed through low body mass index (BMI ⩽18.5 kg/m2) and a low fat-free mass index (FFMI),Citation23 while sarcopenia can be defined as low FFM with a normal or elevated BMI.Citation24 Although somewhat disputed,Citation25 the vitamin D receptor (VDR) has been detected in skeletal muscle cellsCitation26 and low vitamin D status has been associated with a higher risk of sarcopenia and impaired muscle function in older individuals.Citation27 Nonetheless, the majority of studies investigating the potential benefit of optimal vitamin D in COPD patients have focused on respiratory outcomes, with a dearth of studies considering its impact on the maintenance of muscle mass and function. One recent study reported that vitamin D deficient COPD patients had significantly lower handgrip strength and knee flexor muscle strength compared to vitamin D sufficient patients,Citation28 whereas other studies have produced variable results.Citation29Citation32

Seasonal variations in respiratory infections and exacerbations have been reported in COPD patientsCitation33,Citation34 and are comparable to the seasonal variation in vitamin D status.Citation35 Nonetheless, seasonality is a poorly considered aspect of most vitamin D studies in COPD populations. Therefore, the primary aim of this study was to investigate the seasonality of vitamin D status in COPD patients. Secondary aims were to investigate if muscle strength and QoL were predicted by vitamin D status.

Patients and methods

Patients

Individuals with diagnosed stable COPD were recruited from the Belfast and Western Health and Social Care Trusts within Northern Ireland (53–55°N), at community dietician home visits and pulmonary rehabilitation clinics. Exclusion criteria were: ⩽18 year old, pregnancy or having a diagnosis of lung cancer. Patients were given a verbal outline of the study by clinicians, along with a short written information sheet. Following this visit, those patients who expressed interest in the study provided consent for their details to be passed onto a researcher. Interested patients were then contacted via telephone and/or visited by a researcher at their home, where they received a full verbal explanation, full participant information sheet and given at least 48 hours to consider participating in the study. Full written informed consent was obtained from those who participated. This study was approved by The Office for Research Ethics Committee Northern Ireland (12/NI/0183) and was conducted according to the Declaration of Helsinki.

Study design

A researcher visited patients twice at their home over the course of the study: the first at the end of winter (March/April) and the second at the end of summer (September/October), corresponding to the nadir and peak of vitamin D status, respectively. This study took place over two years: 39 patients completed the study between March and October 2013 and the remaining 12 patients completed the study between March and October 2014. Using data from a previous study investigating seasonal differences in vitamin D status in older adults in this population,Citation36 it was calculated that to achieve a power of 80% and a level of significance of 5% (one sided), and allowing for a 40% dropout rate, a minimum of 44 patients should be recruited to see a significant seasonal difference in 25(OH)D concentrations.

Questionnaires

Health and lifestyle questionnaires were completed at both time points for information on smoking status, sun exposure habits and medical history. Patients self-defined themselves as being housebound or nonhousebound according to whether they spent the majority of their waking hours at home or not. This definition was confirmed by the researcher using responses from the sun exposure habits section of the health and lifestyle questionnaire which estimated time spent outdoors during April to September. Daily number of cigarettes and number of years smoking were used to calculate “smoking pack years” as:

Smokingpackyears:(numberofcigarettesdaily×yearssmoking)/20

A validated St George’s Respiratory Questionnaire (SGRQ) was also completed at both time points to assess QoL.Citation37 SGRQ scores were out of 100, with 100% indicating the most lifestyle limitations or poorest QoL.

Anthropometry and muscle strength

Height (m) was measured at the first time point using a portable stadiometer (Seca, Hamburg, Germany). Weight (kg), BMI, (kg/m2) and FFM (kg) were measured at both time points by bioelectrical impedance analysis, using portable Tanita scales (Tanita Corporation, Tokyo, Japan). FFMI (kg/m2) was calculated by correcting FFM for height (FFM (kg)/height (m2)). Muscle strength (kg) was measured at both time points using a Smedley handgrip dynamometer (Stoelting, IL, USA). Three repetitions of a maximal isometric contraction were performed on the nondominant arm, with 30 seconds rest between repetitions. Average of the three repetitions was calculated as overall grip strength and patients who were unable to complete all three repetitions had the average of two repetitions recorded.

Biochemical analysis

Nonfasting 10 mL blood samples were collected by venipuncture into blood collection tubes by a fully trained phlebotomist at both time points and were processed to serum/plasma within 4 hours of collection. Aliquots were stored at −80°C until required for batch analysis at the end of the study. Total serum 25(OH)D (sum of 25(OH)D2+25(OH)D3) concentrations were quantified using liquid chromatography-tandem mass spectrometry (LC-MS/MS, API 4000, AB SCIEX, Foster City, CA, USA) following sample preparation according to kit manufacturer guidelines from Chromsystems Instruments & Chemicals GmbH, Munich, Germany (MassChrom® 25-OH-Vitamin D3/D2), at St James’s Hospital, Dublin. This laboratory participates in the vitamin D External Quality Assessment Scheme (DEQAS). Vitamin D insufficiency is classified as 25(OH)D concentrations ⩽50 nmol/L. Plasma intact parathyroid hormone (PTH) concentrations were measured using a manual enzyme-linked immunoassay at Ulster University, with a commercially available kit (MD Bioproducts, Division of Biosciences Inc., Oakdale, MN, USA). All samples were measured in duplicate and the mean of the two replicates calculated, with precision ensured via bi-level quality controls. Serum calcium (Ca+), creatinine, albumin and high sensitivity C-reactive protein (CRP) concentrations were measured using an ILab™ 600 Chemistry Systems autoanalyzer. The normal reference range for CRP was ⩽10 mg/L. Albumin-adjusted Ca+ concentration was calculated using serum albumin and calcium concentrations:

Serumcalcium(mmol/L)+0.8×(40albumin(g/L))

Renal function was assessed by calculating estimated glomerular filtration rate (eGFR, mL/min/1.73 m2), using the age- and sex-specific Modification of Diet in Renal Disease formula:Citation38

186×(serumcreatinine×0.0113)1.154×(age)0.203×(0.742iffemale)

Statistical analysis

Statistical analyses were carried out using SPSS® for Windows™ Version 22.0 (IBM Corporation, Armonk, NY, USA). All variables were tested for normality using Kolmogorov–Smirnov and those data, which were not normally distributed, were log transformed to achieve near normal distribution. Data are presented as mean±SD, unless otherwise stated. Differences in means between the end of winter and end of summer were assessed for vitamin D, muscle and SGRQ outcome variables, using paired t-tests. Spearman’s correlation analysis was used to assess correlations between serum 25(OH)D and CRP concentration, muscle outcomes and SGRQ scores at each time point. Stepwise linear regressions were performed to investigate serum 25(OH)D concentration as a predictor of muscular outcomes – FFM (kg), FFMI (kg/m2), muscle strength (kg) – and SGRQ scores at both time points. Linear regression models included age, sex and smoking status (active, previous or never) as covariates. FFM (kg) was an additional covariate in muscle strength models only. A P-value ⩽0.05 was considered statistically significant throughout.

Results

A total of 51 COPD patients (n=28 males, n=23 females), with a mean±SD age of 68.7±7.2 years, completed both seasonal time points of the study: the end of winter and end of summer. represents the patient characteristics, anthropometry, muscle mass, muscle strength and biochemical parameters at each seasonal time point. There were no significant differences in any of these variables between the two years of recruitment or between the two Health and Social Care Trust areas (data not shown). At the end of winter, 31%, 67% and 2% actively, previously and never smoked, respectively, whereas, at the end of summer, the proportion of active smokers significantly increased to 41%. There were no significant differences in body weight (kg), BMI (kg/m2), FFM (absolute kg or %), FFMI (kg/m2) or muscle strength between the two seasonal time points. Mean values for BMI at both time points were within the overweight BMI category (25.0–29.9 kg/m2).

Table 1 Characteristics of COPD patients at the end of winter and end of summer

At the end of summer 25(OH)D concentrations were significantly higher compared with the end of winter (52.5±30.5 vs 33.7±28.4 nmol/L). A total of 75% and 47% of patients were classified as vitamin D deficient/insufficient (25(OH)D⩽50 nmol/L) at the end of winter and summer, respectively. Nonhousebound (n=35) patients had significantly higher mean±SD 25(OH)D concentration compared with housebound patients (n=16) at the end of summer (57.2±9.9 vs 42.9±4.2 nmol/L, P=0.029), but there was no significant difference at the end of winter (). Nonetheless, both housebound and nonhousebound patients had a significantly higher 25(OH)D concentration at the end of summer compared with at the end of winter (housebound: 42.9 vs 31.1 nmol/L, P=0.006 and nonhousebound: 57.2 vs 35.2 nmol/L, P⩽0.001).

Figure 1 Mean (SE bars) 25(OH)D concentration for housebound (n=16) and nonhousebound (n=35) COPD patients at the end of winter and at the end of summer. Notes: Differences in 25(OH)D concentration between housebound and nonhousebound patients, within each season tested using independent samples t-test and differences in 25(OH)D concentration for each group between each season tested using paired samples t-test (conducted on log transformed data. Dashed lines represent the level of vitamin D sufficiency (25(OH)D ≥50 nmol/L) and deficiency (25(OH)D ⩽25 nmol/L). *P⩽0.05, **P⩽0.001.

Abbreviations: 25(OH)D, 25-hydroxyvitamin D; SE, standard error.
Figure 1 Mean (SE bars) 25(OH)D concentration for housebound (n=16) and nonhousebound (n=35) COPD patients at the end of winter and at the end of summer. Notes: Differences in 25(OH)D concentration between housebound and nonhousebound patients, within each season tested using independent samples t-test and differences in 25(OH)D concentration for each group between each season tested using paired samples t-test (conducted on log transformed data. Dashed lines represent the level of vitamin D sufficiency (25(OH)D ≥50 nmol/L) and deficiency (25(OH)D ⩽25 nmol/L). *P⩽0.05, **P⩽0.001.

While there were statistically significant seasonal differences in albumin-adjusted Ca+ and creatinine concentrations and eGFR, these differences were not considered clinically significant and reflect the associated seasonal changes in 25(OH)D concentrations. There was no significant seasonal variation in PTH or CRP concentration and no significant difference in QoL (SGRQ scores) between the two seasonal time points.

Absolute FFM (kg), FFMI and CRP concentrations were not significantly correlated with serum 25(OH)D concentration at any time point (). Muscle strength was significantly positively, and SGRQ score, negatively associated with serum 25(OH)D concentration at the end of summer, but not at the end of winter. Stepwise linear regression analyses () showed that serum 25(OH)D concentration was not a significant predictor of absolute FFM (kg) or FFMI at either time point but was a significant positive predictor of muscle strength at both time points. Higher serum 25(OH)D concentration significantly predicted a better QoL (lower SGRQ score) at the end of summer, but not the end of winter, after adjusting for age, sex and smoking status. Additional analyses presented in , show that at the end of summer only, vitamin D insufficient (25(OH)D ⩽50 nmol/L) patients had significantly lower muscle strength and QoL (higher SGRQ score) compared to vitamin D sufficient patients (≥50 nmol/L) and are significantly more likely to be housebound.

Table 2 Correlation analysis between serum 25(OH)D concentration and muscle outcomes, quality of life and CRP concentration of COPD patients at the end of winter and end of summer

Table 3 Stepwise linear regression models to investigate 25(OH)D concentration as a predictor of FFM, muscle strength and quality of life in COPD patients at the end of winter and at the end of summer

Table 4 Muscle function outcomes according to vitamin D insufficiency (25(OH)D ⩽50 nmol/L) and sufficiency (≥50 nmol/L) in COPD patients at the end of winter and at the end of summer

Discussion

This is the first prospective study to report seasonal variability in vitamin D status in COPD patients within Northern Ireland, as well as significantly lower vitamin D status in COPD patients who are housebound compared to those who are nonhousebound. In this patient group, serum 25(OH)D concentration also positively predicted muscle strength at both the end of winter and end of summer, and QoL (according to SGRQ scores) at the end of summer. Moreover, those patients who did not achieve a sufficient vitamin D status at the end of summer, when vitamin D status is expected to be at its highest, had significantly lower muscle strength and a lower QoL compared to those whose 25(OH)D concentration reached ≥50 nmol/L.

In this COPD patient cohort, the seasonal variation in 25(OH)D concentrations observed mirror those recently reported in the general healthy older Irish population in The Irish Longitudinal Study on Aging (TILDA),Citation35 although at concentrations ~10–20 nmol/L lower than the healthy cohort. The current findings are comparable to those from other European COPD cohorts.Citation4,Citation32 In contrast, a cross-sectional observation study of COPD patients in Northern Ireland reported no difference in vitamin D status across season of sampling. The study, however, found a higher year-round prevalence of vitamin D insufficiency (79% ⩽50 nmol/L)Citation7; results comparable with the proportion of COPD patients in the current study with insufficient vitamin D status at the end of winter (75%).

The current study has shown that nonhousebound COPD patients have a significantly higher vitamin D status, compared with housebound patients at the end of summer, but not at the end of winter. Vitamin D deficiency/insufficiency is prevalent in three quarters of the overall cohort at the end of winter, but remains prevalent in housebound patients, even at the end of summer, when vitamin D is expected to be highest, reflecting the lack of cutaneous vitamin D synthesis at this latitude (53–55°N) during these months (October to March).Citation39 Similar findings have been reported in other housebound and institutionalized populations with severely reduced opportunity for sunlight exposure, such as nursing home patientsCitation40 and hospitalized COPD patients.Citation5 These findings highlight a policy requirement for vitamin D supplementation to optimize vitamin D status throughout the year in housebound COPD patients and during winter months in nonhousebound patients.

Although there was a significant seasonal variation in 25(OH)D concentration, this was not reflected by seasonal variations in body composition, according to BMI, FFM or FFMI. In addition, FFM and FFMI were not correlated with 25(OH)D concentration at either seasonal time point. Mean BMI at both seasonal time points was within the overweight category (BMI 25.0–29.9 kg/m2), which has been associated with poor vitamin D status in some studies,Citation41,Citation42 including COPD populations.Citation43 Nonetheless, BMI cannot distinguish between fat mass (FM) and FFM, which is particularly important in COPD patients, who are at risk of sarcopeniaCitation22 or sarcopenic obesity (normal BMI but with low FFM and increased FM).Citation44 Despite no significant associations between body composition and 25(OH)D concentration it is encouraging that in a population with a chronic and progressive disease, such as COPD, there is no significant deterioration in FFM over ~6 months.

Compromised muscle strength and physical performance is a common manifestation of vitamin D deficiency in generally healthy older individuals.Citation45,Citation46 The current study has shown that serum 25(OH)D concentration is a positive predictor of muscle strength (as measured by grip strength) at both the end of winter and the end of summer, and this association was stronger at the end of summer, when vitamin D status was higher. Indeed, in the current study, muscle strength was also ~40% higher in patients who reached vitamin D sufficiency at the end of summer compared to those who remained insufficient/deficient, confirming previous observations by others.Citation28 Furthermore, those patients who reached vitamin D sufficiency at the end of summer were also more likely to be nonhousebound patients, reflecting the major source of vitamin D being sun exposure in this cohort. In addition, it is possible, although speculative that those patients who are not housebound may be partaking in more outdoor activities, although physical activity was not assessed as part of this study. Of interest, previous studies have not replicated this association between 25(OH)D concentration and muscle outcomes in COPD patients who are vitamin D replete (25(OH)D ≥50 nmol/L),Citation31 unlike those reported in the current study. Therefore, it is possible that an effect of vitamin D on muscle in COPD patients may only be observed in those who are vitamin D deficient/insufficient at baseline or in patients with particular genetic variations in genes associated with vitamin D metabolism such as FokI and Bsml VDR polymorphisms that have been shown to influence associations between vitamin D and its functions.Citation47 Both of these factors should be considered in future randomized controlled trials in this group.

Genomic and nongenomic mechanisms have been proposed to explain the beneficial effect of vitamin D on muscle and the suggested genomic mechanism, mediated via the VDR, results in proliferation of muscle proteins, predominantly type II muscle fiber proteins.Citation48 This does not seem a plausible mechanism to explain the associations in this study, as we might also expect an increase in FFM owing to increased type II muscle fibers. Rather, the faster intracellular, nongenomic mechanism seems a more appropriate explanation. This mechanism suggests that the active form of vitamin D, 1,25 dihydroxyvitamin D (1,25(OH)2D3) acts upon Ca+ channels on the cell membrane, allowing for an increased flux of intracellular Ca+, improving muscle function and contractility.Citation49 Further investigation is required to determine the exact mechanisms by which vitamin D influences muscle strength in normal populations, as well as those with compromised muscle function, such as those diagnosed with COPD.

Previous literature has suggested the importance of optimal vitamin D status on respiratory function and the frequency of exacerbations in COPD patients,Citation8,Citation12,Citation33,Citation50Citation54 which may also influence winter time mortality rates.Citation34 Although the current study cannot provide information on respiratory function, disease severity or exacerbation frequency, we do report data on CRP concentrations similar to other stable COPD cohortsCitation55 and which may be a possible mediating factor between vitamin D and respiratory function.Citation52 In the current study, CRP did not differ significantly between the seasons and was not correlated with serum 25(OH)D concentration at either time point, a finding that confirms the findings of others.Citation52 Although higher concentrations of CRP have been associated with impaired lung function, the role of CRP in the etiology of COPD and respiratory function remains poorly understood.Citation56,Citation57 Further research is also warranted to elucidate the relationship between vitamin D and immune-respiratory function in COPD.

Disease severity and exacerbations have been shown to considerably impact upon the QoL in COPD patients.Citation58,Citation59 The current study has shown for the first time that higher serum 25(OH)D concentrations are predictive of lower SGRQ scores and thus a better QoL, independent of age, sex and smoking status in COPD patients. These results are in contrast to a Korean COPD population, where no significant association was found between vitamin D status and QoL at similar 25(OH)D concentration.Citation60 It is noteworthy, however, that in the current study, QoL score was assessed by a subjective self-reported questionnaire and it is possible that higher vitamin D status was a result of a better QoL as patients who reported fewer lifestyle limitations were more likely to spend time outdoors. This finding might also explain why the association was evident at the end of summer, when cutaneous vitamin D synthesis was possible from sunlight exposure, but not at the end of winter.

Although this is an observational study, and the findings might not indicate cause and effect, it analyzes the prospective association between vitamin D status, muscle function, CRP and QoL in a group of COPD patients, with a specific focus on seasonality. Another strength is that serum 25(OH)D concentrations were quantified using the gold standard LC-MS/MS method by a laboratory participating in the DEQAS. One limitation of the current study is the absence of data on respiratory function, disease severity and exacerbations, which may have been significant covariates in the current analyzes. Such clinical markers should be routinely measured and recorded for all patients and this monitoring should be reflected in COPD clinical management guidelines and policy. Dietary vitamin D intake, including supplementation, was also not assessed in this study and may be useful for clinicians to help recommend the best strategy to improve intake and increase status as necessary.

In conclusion, to the authors’ knowledge, this is the first prospective study to demonstrate the seasonality of vitamin D status in COPD patients and importantly noting these differences between housebound and nonhousebound patients. Moreover, specifically at the end of summer, housebound COPD patients had significantly lower vitamin D status compared to nonhousebound patients, and worryingly, a greater proportion remained deficient/insufficient at this time point when vitamin D status should have been at its highest. This finding demonstrates the efficacy of cutaneous vitamin D synthesis from sunlight exposure and highlights the importance of optimizing QoL in this at-risk patient group to facilitate time spent outdoors regularly. Currently vitamin D is not considered as part of the recommended management of COPD by the National Institute for Health and Care Excellence guidelines in the UK, but the recently revised reference nutrient intake of 10 μg/day (400 IU) for the general population should apply to this population and assumes minimal sunshine exposure.Citation61 Findings from the current study may directly impact on policy as they suggest a requirement for year-round vitamin D supplementation particularly for housebound COPD patients and during winter for nonhousebound patients, as a relatively inexpensive and effective means of optimizing vitamin D status and not least maintaining 25(OH)D concentrations to protect musculoskeletal health. The potential positive influence of optimal vitamin D on muscle strength and QoL, as reported in the current study, may in turn lead to improved exercise tolerance, physical function and slower deterioration of respiratory function in COPD patients. Such results should also help inform health care and professional and patient education programs and policy on vitamin D supplementation in this population group with the ultimate aim to ensure adequate vitamin D status in patients with COPD.

Acknowledgments

The authors wish to thank all patients who participated in the study and the respiratory nurses who assisted with sample collection. The study was jointly funded by the Western Health and Social Care Trust Research Office and the Biomedical Sciences Research Institute, Ulster University. The funding sources had no input into the study design, collection, analysis or interpretation of the data and/or production of the manuscript.

Disclosure

The authors report no conflicts of interest in this work.

References

  • HughesDANortonRVitamin D and respiratory healthClin Exp Immunol20091581202519737226
  • Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary DiseaseGlobal Initiative for Chronic Obstructive Lung Disease website Available from: http://www.gold-copd.org/guidelines-global-strategy-for-diagnosismanagement.htmlAccessed 5th July 2017
  • JanssensWBouillonRClaesBVitamin D deficiency is highly prevalent in COPD and correlates with variants in the vitamin D-binding geneThorax201065321522019996341
  • PerssonLJPAanerudMHiemstraPSHardieJABakkePSEaganTMLChronic obstructive pulmonary disease is associated with low levels of vitamin DPLoS One201276e3893422737223
  • MekovESlavovaYTsakovaAVitamin D deficiency and insufficiency in hospitalized COPD patientsPLoS One2015106e012908026047485
  • RommeEARuttenEPSmeenkFWSpruitMAMenheerePPWoutersEFVitamin D status is associated with bone mineral density and functional exercise capacity in patients with chronic obstructive pulmonary diseaseAnn Med2013451919622462562
  • BaldrickFRElbornJSWoodsideJVVitamin D status in chronic obstructive pulmonary diseaseProc Nutr Soc201271E98
  • MalinovschiAMasoeroMBellocchiaMSevere vitamin D deficiency is associated with frequent exacerbations and hospitalization in COPD patientsRespir Res201415113125496239
  • KokturkNBahaAOhYMYoung JuJJonesPWVitamin D deficiency: what does it mean for chronic obstructive pulmonary disease (COPD)? A comprehensive review for pulmonologistsClin Respir J201812238239727925404
  • ZhuBZhuBXiaoCZhengZVitamin D deficiency is associated with the severity of COPD: a systematic review and meta-analysisInt J Chron Obstruct Pulmon Dis2015101907191626392765
  • ZhuMWangTWangCJiYThe association between vitamin D and COPD risk, severity, and exacerbation: an updated systematic review and meta-analysisInt J Chron Obstruct Pulmon Dis2016112597260727799758
  • MartineauARJamesWYHooperRLVitamin D3 supplementation in patients with chronic obstructive pulmonary disease (ViDiCO): a multicentre, double-blind, randomised controlled trialLancet Respir Med20153212013025476069
  • HeulensNKorfHJanssensWInnate immune modulation in chronic obstructive pulmonary disease: moving closer toward vitamin D therapyJ Pharmacol Exp Ther2015353236036825755208
  • CantornaMTHumpal-WinterJDelucaHFIn vivo upregulation of interleukin-4 is one mechanism underlying the immunoregulatory effects of 1,25-dihydroxyvitamin D3Arch Biochem Biophys2000377113513810775452
  • BemissCJMahonBDHenryAWeaverVCantornaMTInterleukin-2 is one of the targets of 1,25-dihydroxyvitamin D3 in the immune systemArch Biochem Biophys2002402224925412051670
  • van der MolenTCo-morbidities of COPD in primary care: frequency, relation to COPD, and treatment consequencesPrim Care Respir J201019432633420842323
  • Garcia-AymerichJSerra PonsIManninoDMMaasAKMillerDPDavisKJLung function impairment, COPD hospitalisations and subsequent mortalityThorax201166758559021515553
  • KimHCMofarrahiMHussainSNSkeletal muscle dysfunction in patients with chronic obstructive pulmonary diseaseInt J Chron Obstruct Pulmon Dis20083463765819281080
  • MaltaisFDecramerMCasaburiRAn official American Thoracic Society/European Respiratory Society statement: update on limb muscle dysfunction in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med20141899e15e6224787074
  • SundhJJohanssonGLarssonKComorbidity and health-related quality of life in patients with severe chronic obstructive pulmonary disease attending Swedish secondary care unitsInt J Chron Obstruct Pulmon Dis20151017318325653516
  • GologanuDIonitaDGartoneaTStanescuCBogdanMABody composition in patients with chronic obstructive pulmonary diseaseMaedica201491253225553122
  • JeonYKShinMJKimMHLow pulmonary function is related with a high risk of sarcopenia in community-dwelling older adults: the Korea National Health and Nutrition Examination Survey (KNHANES) 2008–2011Osteoporos Int201526102423242925956284
  • von HaehlingSAnkerSDPrevalenceASDPrevalence, incidence and clinical impact of cachexia: facts and numbers-update 2014J Cachexia Sarcopenia Muscle20145426126325384990
  • RoubenoffRSarcopenia: effects on body composition and functionJ Gerontol A Biol Sci Med Sci20035811M1012M1017
  • WangYDelucaHFIs the vitamin d receptor found in muscle?Endocrinology2011152235436321190957
  • GarciaLAFerriniMGNorrisKCArtazaJN1,25(OH)(2)vitamin D(3) enhances myogenic differentiation by modulating the expression of key angiogenic growth factors and angiogenic inhibitors in C(2)C(12) skeletal muscle cellsJ Steroid Biochem Mol Biol201313311122982629
  • TielandMBrouwer-BrolsmaEMNienaber-RousseauCvan LoonLJde GrootLCLow vitamin D status is associated with reduced muscle mass and impaired physical performance in frail elderly peopleEur J Clin Nutr201367101050105523942175
  • YumrutepeTAytemurZABaysalOTaskapanHTaskapanCMHacievliyagilSSRelationship between vitamin D and lung function, physical performance and balance on patients with stage I–III chronic obstructive pulmonary diseaseRev Assoc Med Bras201561213213826107362
  • HornikxMvan RemoortelHLehouckAVitamin D supplementation during rehabilitation in COPD: a secondary analysis of a randomized trialRespir Res2012138423006613
  • BjerkSMEdgingtonBDRectorTSKunisakiKMSupplemental vitamin D and physical performance in COPD: a pilot randomized trialInt J Chron Obstruct Pulmon Dis201389710423430315
  • JacksonASShrikrishnaDKellyJLVitamin D and skeletal muscle strength and endurance in COPDEur Respir J201341230931622556020
  • RafiqRPrinsHJBoersmaWGEffects of daily vitamin D supplementation on respiratory muscle strength and physical performance in vitamin D-deficient COPD patients: a pilot trialInt J Chron Obstruct Pulmon Dis2017122583259228894361
  • JenkinsCRCelliBAndersonJASeasonality and determinants of moderate and severe COPD exacerbations in the TORCH studyEur Respir J2012391384521737561
  • DonaldsonGCWedzichaJAThe causes and consequences of seasonal variation in COPD exacerbationsInt J Chron Obstruct Pulmon Dis201491101111025336941
  • LairdEO’HalloranAMCareyDThe prevalence of vitamin D deficiency and the determinants of 25(OH)D concentration in older Irish adults: Data from The Irish Longitudinal Study on Ageing (TILDA)J Gerontol A Biol Sci Med Sci2017734519522
  • BatesBLennoxAPrenticeABatesCPagePNicholsonSThe National Diet and Nutrition Survey: Results from years 1, 2, 3 and 4 (combined) of the rolling programme (2008/2009–2011/2012)LondonTSO2014
  • JonesPWQuirkFHBaveystockCMThe St George’s Respiratory QuestionnaireRespir Med199185Suppl B25311759018
  • LeveyASBoschJPLewisJBGreeneTRogersNRothDA more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study GroupAnn Intern Med1999130646147010075613
  • WebbARKlineLHolickMFInfluence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skinJ Clin Endocrinol Metab19886723733782839537
  • VerhoevenVVanpuyenbroeckKLopez-HartmannMWensJRemmenRWalk on the sunny side of life – epidemiology of hypovitaminosis D and mental health in elderly nursing home residentsJ Nutr Health Aging201216441742022499468
  • SnijderMBvan DamRMVisserMAdiposity in relation to vitamin D status and parathyroid hormone levels: a population-based study in older men and womenJ Clin Endocrinol Metab20059074119412315855256
  • PourshahidiLKVitamin D and obesity: current perspectives and future directionsProc Nutr Soc201574211512425359323
  • JolliffeDAJamesWYHooperRLPrevalence, determinants and clinical correlates of vitamin D deficiency in patients with chronic obstructive pulmonary disease in London, UKJ Steroid Biochem Mol Biol201817513814528161533
  • BioloGCederholmTMuscaritoliMMuscle contractile and metabolic dysfunction is a common feature of sarcopenia of aging and chronic diseases: from sarcopenic obesity to cachexiaClin Nutr201433573774824785098
  • IolasconGde SireACalafioreDMorettiAGimiglianoRGimiglianoFHypovitaminosis D is associated with a reduction in upper and lower limb muscle strength and physical performance in post-menopausal women: a retrospective studyAging Clin Exp Res201527Suppl 12330
  • SalminenMSaaristoPSalonojaMVitamin D status and physical function in older Finnish people: a one-year follow-up studyArch Gerontol Geriatr201561341942426321481
  • HopkinsonNSLiKWKehoeAVitamin D receptor genotypes influence quadriceps strength in chronic obstructive pulmonary diseaseAm J Clin Nutr200887238539018258629
  • Barton-DavisERShoturmaDIMusaroARosenthalNSweeneyHLViral mediated expression of insulin-like growth factor I blocks the aging-related loss of skeletal muscle functionProc Natl Acad Sci U S A1998952615603156079861016
  • BerchtoldMWBrinkmeierHMüntenerMCalcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and diseasePhysiol Rev20008031215126510893434
  • RabeKFFabbriLMVogelmeierCSeasonal distribution of COPD exacerbations in the Prevention of Exacerbations with Tiotropium in COPD TrialChest2013143371171923188489
  • LehouckAMathieuCCarremansCHigh doses of vitamin D to reduce exacerbations in chronic obstructive pulmonary disease: a randomized trialAnn Intern Med2012156210511422250141
  • HendryxMLuoJA test of vitamin D benefits on respiratory health mediated through inflammatory markersChron Respir Dis2015121243025336462
  • FlexederCThieringEKoletzkoSHigher serum 25(OH)D concentrations are associated with improved FEV1 and FVC in adolescenceEur Respir J2017494160180428446555
  • SluyterJDCamargoCAWaayerDEffect of monthly, high-dose, long-term vitamin D on lung function: a randomized controlled trialNutrients2017912E135329236049
  • AksuFÇapanNAksuKC-reactive protein levels are raised in stable chronic obstructive pulmonary disease patients independent of smoking behavior and biomass exposureJ Thorac Dis20135441442123991296
  • MendyAFornoENiyonsengaTGasanaJBlood biomarkers as predictors of long-term mortality in COPDClin Respir J201711
  • WalterREWilkJBLarsonMGSystemic inflammation and COPD: the Framingham Heart StudyChest20081331192517908709
  • SeemungalTADonaldsonGCPaulEABestallJCJeffriesDJWedzichaJAEffect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med19981575 Pt 1141814229603117
  • PeruzzaSSergiGVianelloAChronic obstructive pulmonary disease (COPD) in elderly subjects: impact on functional status and quality of lifeRespir Med200397661261712814144
  • ParkJHParkHKJungHLeeSSKooHKParathyroid hormone as a novel biomarker for chronic obstructive pulmonary disease: Korean National Health and Nutrition Examination SurveyPLoS One2015109e013848226398210
  • SACNThe Scientific Advisory Committee on Nutrition (SACN) Recommendations on Vitamin DEnglandPublic Health England2016